ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Arkansas » Pulmonary Disease

Top Pulmonary Disease Prescribers in Arkansas

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
MARK MOSELEY M.D.

Pulmonary Disease

10,904

$529K

190
176 are 65+

15%
patients receiving schedule two controlled substances

Avg: 1%

38%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 59%

$48
Average prescription price

Avg: $164

TYRONE LEE M.D.

Pulmonary Disease

5,949

$1.15M

555
424 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

81%
prescriptions for brand name drugs

Avg: 59%

$193
Average prescription price

Avg: $164

NANCY RECTOR M.D.

Pulmonary Disease

3,643

$748K

457
364 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

57%
prescriptions for brand name drugs

Avg: 59%

$205
Average prescription price

Avg: $164

ARTURO MEADE MD

Pulmonary Disease

3,279

$628K

407
277 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

6%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

65%
prescriptions for brand name drugs

Avg: 59%

$192
Average prescription price

Avg: $164

RAUL RAMIREZ M.D.

Pulmonary Disease

3,264

$160K

187
124 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

16%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

19%
prescriptions for brand name drugs

Avg: 59%

$49
Average prescription price

Avg: $164

ALBERT CHINN MD

Pulmonary Disease

3,203

$377K

307
234 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

57%
prescriptions for brand name drugs

Avg: 59%

$118
Average prescription price

Avg: $164

JAMES CAMPBELL M.D.

Pulmonary Disease

2,386

$335K

226
162 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

50%
prescriptions for brand name drugs

Avg: 59%

$140
Average prescription price

Avg: $164

HANAN MAKHOUL MD

Pulmonary Disease

2,360

$546K

268
220 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

52%
prescriptions for brand name drugs

Avg: 59%

$231
Average prescription price

Avg: $164

JON SEXTON MD

Pulmonary Disease

2,076

$315K

278
219 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

66%
prescriptions for brand name drugs

Avg: 59%

$152
Average prescription price

Avg: $164

MARK SIFFORD MD

Pulmonary Disease

2,055

$442K

419
259 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

3%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 59%

$215
Average prescription price

Avg: $164

MADHU KALYAN MD

Pulmonary Disease

2,031

$330K

388
242 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

49%
prescriptions for brand name drugs

Avg: 59%

$162
Average prescription price

Avg: $164

GARY TEMPLETON MD

Pulmonary Disease

1,857

$265K

263
198 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

68%
prescriptions for brand name drugs

Avg: 59%

$143
Average prescription price

Avg: $164

MEREDITH WALKER M.D.

Pulmonary Disease

1,812

$223K

308
230 are 65+

4%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

45%
prescriptions for brand name drugs

Avg: 59%

$123
Average prescription price

Avg: $164

KYLE HARDY MD

Pulmonary Disease

1,720

$423K

253
182 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

80%
prescriptions for brand name drugs

Avg: 59%

$246
Average prescription price

Avg: $164

SARA MARTIN M.D.

Pulmonary Disease

1,588

$295K

305
210 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

63%
prescriptions for brand name drugs

Avg: 59%

$186
Average prescription price

Avg: $164

EDWARD JACKSON M.D.

Pulmonary Disease

1,270

$358K

236
182 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

77%
prescriptions for brand name drugs

Avg: 59%

$282
Average prescription price

Avg: $164

IRAM BAKHTAWAR M.D..

Pulmonary Disease

1,252

$208K

190
148 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

59%
prescriptions for brand name drugs

Avg: 59%

$166
Average prescription price

Avg: $164

IDREES MOGRI MD

Pulmonary Disease

1,229

$214K

246
184 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

76%
prescriptions for brand name drugs

Avg: 59%

$174
Average prescription price

Avg: $164

GAIL MCCRACKEN MD

Pulmonary Disease

1,206

$195K

189
157 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

78%
prescriptions for brand name drugs

Avg: 59%

$162
Average prescription price

Avg: $164

KIRKLAND NOLAN MD

Pulmonary Disease

1,160

$176K

191
161 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

12%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

56%
prescriptions for brand name drugs

Avg: 59%

$152
Average prescription price

Avg: $164

MAHER DAHDEL MD

Pulmonary Disease

1,102

$183K

247
150 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

76%
prescriptions for brand name drugs

Avg: 59%

$166
Average prescription price

Avg: $164

EYAD ABOCHALE M.D.

Pulmonary Disease

998

$229K

243
182 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

61%
prescriptions for brand name drugs

Avg: 59%

$230
Average prescription price

Avg: $164

PAULA ANDERSON MD

Pulmonary Disease

994

$353K

67
30 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

59%
prescriptions for brand name drugs

Avg: 59%

$355
Average prescription price

Avg: $164

ROBERT SANDERS MD

Pulmonary Disease

957

$49.4K

75
54 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

28%
prescriptions for brand name drugs

Avg: 59%

$52
Average prescription price

Avg: $164

WILLIAM HUBBARD M.D.

Pulmonary Disease

842

$82.8K

170
138 are 65+

8%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 59%

$98
Average prescription price

Avg: $164

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank